Drug Trial Radar · NCT06836557
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Jan 9, 2024
Primary completion
Mar 30, 2026
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.
Conditions
- Idiopathic Gastroparesis
- Diabetic Gastroparesis
- Gastroparesis
Interventions
TradipitantDrug
BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs), including suicidal ideation or behavior as measured by the C-SSRSTime frame: 12 weeks
- Number of participants with changes in vital signs identified as Clinically Notable Abnormal valuesTime frame: 12 weeks
- Number of participants with abnormal and potentially Clinically Notable Abnormal Electrocardiogram Intervals and Heart RateTime frame: 12 weeks
- Number of participants with Clinically Notable Abnormal laboratory valuesTime frame: 12 weeks
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Vanda Investigational Site
Leuven, Belgium
Vanda Investigational Site
Liège, Belgium
Vanda Investigational Site
Leipzig, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.